This manuscript reports on a phase II study evaluating the safety and efficacy of letrozole +/-AS1402 in the treatment of hormone receptor positive (HR+) metastatic breast cancer (MBC). The main conclusions of clinical relevance are:
INTRODUCTION
For the past 30 years, the selective estrogen receptor (ER) modulator tamoxifen has been the standard of care in much of the Western world for hormone-responsive advanced breast cancer in both premenopausal and postmenopausal women, mainly because of its favorable safety profile (1) (2) (3) . Results from randomized trials (4, 5) , and a meta-analysis (6), suggest that when used as first-line therapy for metastatic breast cancer, third-generation aromatase inhibitors, such as letrozole, are associated with superior response rates, time to progression (TTP), and overall survival compared to first-line tamoxifen. However, hormone receptor (HR)-positive advanced breast cancer remains an area of unmet medical need, because most patients will eventually die from their disease.
MUC1 is an aberrantly glycosylated antigen over expressed in approximately 90% of breast cancer tumors (7). It stimulates ER alpha (ER-α) mediated transcription and contributes to estrogen-mediated growth and survival of breast cancer cells in vitro.
MUC1 activates and stabilizes ER-α by binding to the DNA-binding domain of the receptor (8). This MUC1-ER dynamic may be the basis for the clinical finding of prolonged survival in breast cancer patients vaccinated with Theratope and given concomitant hormonal therapy, compared to a control group receiving the vaccination only. Median survival times in the two groups were 36.5 months and 30.7 months, respectively, in a retrospective sub-group analysis (9). Theratope is a vaccine based on Sialyl-Tn, a carbohydrate associated with MUC1. AS1402 is a humanized immunoglobulin G1 kappa (IgG1 κ) monoclonal antibody that targets MUC1. Its antitumor activity has been demonstrated in vitro with an antibody-dependent cell-mediated cytotoxicity (ADCC) assay (10). AS1402 plasma concentrations similar to the concentrations necessary to elicit ADCC in vitro were achieved in a phase I dose escalation study (11).
Here, we report the findings of a phase II, randomized, open-label, international study designed to compare the efficacy, safety, and tolerability of AS1402 in combination with letrozole to that of letrozole only as first-line treatment in postmenopausal women with HR-positive/HER2-negative locally advanced or metastatic breast cancer. The combination of AS1402 with an aromatase inhibitor in this study was predicated upon preclinical pharmacology demonstrating a mechanistic interaction between the MUC1 oncoprotein and the ER (12, 13) .
The in vitro finding that aromatase inhibitor pretreatment sensitized malignant breast tissue to monocyte-mediated ADCC further extends the body of evidence underpinning the potential clinical utility of a combined therapeutic approach (14) , with AS1402 mediating ADCC at the MUC1 level and an aromatase inhibitor acting at the ER level.
Natural killer cells, the principal mediators of ADCC, constitutively express FcγRIIIa, and macrophages, also contributing to ADCC, express FcγRIIIa and FcγRIIa (15 
MATERIALS AND METHODS

Study Population
This was a randomized, international, open-label phase II study of postmenopausal women with metastatic or locally advanced breast cancer not amenable to curative therapy. One hundred and ten patients were enrolled at 22 sites in the United States, Poland, Ukraine, and Russia.
Patients were eligible for the study if they had ER-positive and/or progesterone receptor (PR)-positive histologically or cytologically confirmed breast cancer; had measureable disease according to Response Evaluation Criteria in Solid Tumors (RECIST); were past natural or therapy-induced menopause; had Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1; and had a granulocyte count ≥ 1.0x10 9 /l, platelet count ≥ 100x10 9 /l, bilirubin levels ≤ 2 times the upper limit of normal, aspartate transaminase and alanine transaminase levels ≤ 5 times the upper limit of normal, and creatinine clearance ≥ 30 ml/min. Patients were excluded if they had undergone prior chemotherapy or endocrine therapy; had a relapse ≤1 year after discontinuation of adjuvant therapy including an aromatase inhibitor; had HER2/neupositive breast cancer; or had any other concurrent disease or condition precluding study compliance.
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Study Conduct
The study was sponsored by Antisoma Research Ltd. Enrollment was started only after the study protocol was approved by the local institutional review board, ethics committee, and/or regulatory agency for each study site. All study participants provided signed informed consent prior to initiating any study related procedures.
Treatment
All subjects received 2.5 mg letrozole orally (Novartis AG, Basel, Switzerland) once daily. Subjects randomized to the experimental arm received AS1402 (Antisoma Research Ltd., London, UK) as a weekly 1-hour 9 mg/kg infusion. Patients were treated until disease progression or withdrawal.
Study Assessments
The primary objective of this study was to compare the overall tumor response rates between the treatment arms. The secondary endpoints were TTP, progression-free survival (PFS), clinical benefit rate, duration of response and safety. Tumor assessments were to be performed according to RECIST upon enrollment and every 12 weeks thereafter until disease progression, or when clinical examination suggested disease progression. Radiology scans were submitted for independent review. 
Statistical Analysis
Patients were randomized 1:1 to receive letrozole and AS1402 (experimental arm) or letrozole only (control arm). The randomization was stratified for the presence of visceral disease and for the administration of prior adjuvant endocrine therapy.
Simon's minimax 2-stage design was used with the stopping criteria applied to the AS1402 + letrozole arm only (22). If three or fewer confirmed responses were seen within the first 6 months of treatment in the first 31 patients randomized to the experimental arm, the trial was to be stopped. Otherwise, additional patients were to be randomized until 55 patients were accrued for each treatment arm. The final sample size was selected to have a 90% power to detect a true response rate ≥ 25% in the experimental arm. The efficacy hurdle was designed to ensure the combination therapy of AS1402+letrozole was not inferior to the standard letrozole therapy in terms of historical response rates. The response rates for each arm and 95% confidence intervals (CIs) for the estimates were calculated. PFS and TTP were calculated from the date of randomization.
Median PFS and median TTP were calculated with Kaplan-Meier analyses. The CIs for median estimates were based on the Brookmeyer and Crowley method. Treatment effect estimates and 95% CIs were based on a Cox proportional hazards regression model, both unadjusted and adjusted for randomization stratification factors. All outcomes related to disease progression and responses were based on investigatorreported data collected on case report forms.
Allotyping
Venous blood was collected from each patient and frozen. DNA was extracted at the central laboratory from 200 µl blood using the QIAamp Blood Mini Kit from Qiagen (Valencia, CA). The DNA yield was measured using a ND-1000 Nanodrop spectrophotometer from Thermo Fischer Scientific (Waltham, MA). run in duplicate. Every reaction plate had a triplicate non-template control (NTC).
Genotypes were detected by allele-specific fluorescence using the SDS 1.2.3 software (Applied Biosystems).
Selected samples were sequenced and the PCR was performed in two separate laboratories to ensure reliable results (data not shown).
RESULTS
Demographics and Treatment
A total of 110 patients were enrolled and 109 treated in the study between August 29, 2008, and April 15, 2009 (figure 1). There were no notable differences between the AS1402 + letrozole arm and the letrozole-only arm in any baseline demographic variable ( Table 1 ).
The mean actual dose intensity of administered AS1402 was 8.8 mg/kg/week, or 98% of the target dose intensity. The mean cumulative actual dose of administered letrozole was 406.4 mg for patients in the AS1402 + letrozole arm and 431.2 mg for patients in the letrozole-only arm. The 6% lower mean cumulative actual letrozole dose in the AS1402 + letrozole arm is unlikely to represent a clinically relevant difference.
Early Termination of the Study
The study recruited faster than expected, hence the study was fully recruited before the stage 1 analysis could be performed. A scheduled DMC review of the data on 
letrozole arm. In addition the number of patients who had withdrawn from the study because of disease progression was considerably higher in the AS1402 + letrozole arm, resulting in a shorter estimated PFS in the AS1402 + letrozole arm than in the letrozole only arm. After discussion with the DMC, a detailed analysis of the reasons of discontinuation (see Figure 1) , available biomarker and PK data, and a thorough statistical analysis, the study sponsor concluded that the study was highly unlikely to yield a positive final result, and administration of AS1402 was stopped on August 7, 2009, to prevent unnecessarily exposing subjects to AS1402 when it was highly unlikely the final results of the study would support further development of AS1402.
Safety Results
There was no notable difference between the AS1402 + letrozole arm and the letrozole-only arm in the incidence or severity of AEs, as displayed in Table 2 . AEs were reported in 60.7% and 66.0% of patients, respectively. No grade 5 AEs were reported during safety assessments in either arm. However, five patients on the letrozole arm died from disease progression before the study was terminated. The only Grade 4 AE reported was one case of anemia in the letrozole-only arm. Grade 3 AEs were reported in one patient (1.8%) in the AS1402 + letrozole arm compared with 9 patients (17.0%) in the letrozole-only arm. The most frequently reported AEs were hot flush, asthenia, fatigue, arthralgia, cough, and hypertension.
AEs considered to be related to AS1402 were reported in 18 patients (32.1%; Table   3 ). All were classified as ≤Grade 2. There was no notable difference between the experimental and control arms in the incidence of AEs considered to be related to letrozole (28.6% and 32.1%, respectively; data not shown).
Efficacy Results
Partial response to treatment was reported in a lower proportion of patients in the AS1402 + letrozole arm (7 patients, 12.5%) than in the letrozole-only arm (14 patients, 25.9%). Stable disease was reported in 32 patients (57.1%) in the AS1402 + letrozole arm and in 27 patients (50.0%) in the letrozole-only arm, and progressive disease was reported in 13 patients (23.2%) in the AS1402 + letrozole arm and in 10 patients (18.5%) in the letrozole-only arm. The difference in response rates (AS1402 + letrozole vs. letrozole only) was 13.43% with a CI of -27.975-1.12% implying a lack of treatment difference between the arms.
Results of the PFS and TTP analyses were the same, as everyone who died had disease progression (Figure 2 
FcγRIIIa, FcγRIIa, and MUC1 Allotypes
Samples from 105 patients (95%) were successfully allotyped. For FcγRIIIa 158, the allotypes were F/F for 46 patients (44%), F/V for 51 patients (49%), and V/V for 8
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on October 16, 2017. © 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. patients (8%). For FcγRIIa, the allotypes were H/H for 30 patients (29%), H/R for 58 patients (55%), and R/R for 17 patients (16%). For MUC1, the allotypes were G/G for 32 patients (30%), A/G for 51 patients (49%), and A/A for 22 patients (21%). The distribution of the evaluated allotypes was thus in line with previous reports in this white Caucasian population (20, 23).
The waterfall diagrams presented in Figure 3 are color coded for each allotype.
Analysis of the allotypes did not reveal any specific subgroup associated with a favorable or adverse outcome when change in tumor burden measured according to RECIST was used as measure of outcome. This result provided additional support for stopping the study early.
Evaluation of PK, HAHA, and MUC1 Expression
Because the study was terminated early, the planned full evaluation of population PK parameters, HAHA levels, and MUC1 expression was not performed. PK samples evaluated prior to the termination of the study exhibited AS1402 concentrations in line with expectations based on the prior phase I study (11). MUC1 expression has previously been reported in >90% of patients with breast cancer (7), and in the phase I study of AS1402, none of the 29 treated patients developed HAHA (11). HAHA levels and MUC1 expression were therefore not evaluated, as they were unlikely to affect the overall interpretation of the trial results. 
DISCUSSION
The final data from this study failed to provide evidence of increased efficacy when AS1402 is added to letrozole. The study was a randomized phase II study designed to compare AS1402 in combination with letrozole to letrozole only as a first-line treatment in postmenopausal women with locally advanced or metastatic breast cancer. The study was terminated when a review indicated a trend toward a higher proportion of patients with disease progression and a smaller proportion of patients responding to treatment in the AS1402 + letrozole arm than in the letrozole-only arm.
AS1402 has previously been shown to localize to MUC1-positive tumor sites (24), MUC1 has been shown to be present in approximately 90% of breast cancers (7), and the expected AS1402 plasma concentrations were achieved in this study. There was no evidence of an increase in the size of lymph node lesions compared with other target lesions, and thus the lower response rate and increased rate of disease progression in the AS1402 + letrozole arm was not due to AS1402 causing reactively enlarged lymph nodes (data not shown). Furthermore, the sites and types of disease progression were similar in the AS1402 + letrozole arm and the letrozole-only arm.
The lack of efficacy noted in this study is therefore unlikely to be due to methodological issues. 
The failure of this study to meet the primary objective demonstrates a lack of clinical synergy between an anti-MUC1 agent and an aromatase inhibitor. The finding conflicts with preclinical data describing the modulation by MUC1 of the ER (8, 25).
The mere inhibition of systemic estrogen production may not influence the regulation pathway affected by the modulation of ER by MUC1. It is conceivable that blockage of the ER, which may be achieved with the use of tamoxifen or fulvestrant, would synergize with AS1402. Therefore, combining AS1402 with tamoxifen or fulvestrant may yield different clinical results. Alternatively, one may conclude that the preclinical data could not be substantiated by this study and might call for redefining the significance of ER modulation by MUC1.
Other antibodies than AS1402 relying primarily on ADCC for tumor cell kill are particularly efficacious in certain patient subsets with specific FcγIIIRa and FcγIIRa allotypes (17-19). This study did not show enhanced efficacy, measured as change in tumor burden from baseline, in any patient subgroup defined by the tested allotypes.
This was true for both study arms. It is therefore likely that ADCC does not contribute significantly to the efficacy of estrogen depletion in HR-positive breast cancer, irrespective of AS1402 treatment.
The lower response rate noted in the AS1402 + letrozole arm compared with the letrozole-only arm was likely due to random chance in a small study, as the waterfall diagrams were similar for both arms (Fig. 3) and as the 95% CI for the difference in response rate contained 0.
The higher number of patients who withdrew consent during therapy in the AS1402 + letrozole arm may be explained by the requirement for weekly visits during therapy with AS1402.
Overall, the incidence of AEs reported in the study was low compared with the results of previous reports on the safety of letrozole in the advanced breast cancer setting (4).
This finding may be explained by the early termination of the study, which limited the duration of safety follow-up. AEs considered to be related to AS1402 were reported in only 32% of patients receiving AS1402, and all were of low grades. Liver enzyme elevation was noted in both arms, but primarily in patients with liver metastases and disease progression.
In conclusion, the combination of AS1402 and letrozole exhibited a favorable safety 
